塞来昔布对人肝癌细胞株HepG2细胞核转录因子-κB活性及蛋白表达的抑制

Celecoxib inhibited activation of NF-κB and expression of NF-κB P65 protein in HepG2 cells

目的:探讨环氧合酶-2选择性抑制剂塞来昔布(celecoxib)对人肝癌细胞株HepG2细胞核转录因子-κB(nuclear factor-kappa B,NF-κB)活性和蛋白表达的影响.方法:不同浓度的塞来昔布作用于HepG2细胞后,应用凝胶电泳迁移率改变分析技术检测HepG2细胞中NF-κBDNA结合活性;用Western blotting法检测HepG2细胞NF-κBp65蛋白表达.结果:25、50μmol/L塞来昔布作用于HepG2细胞后,药物处理组HepG2细胞NF-κBDNA结合活性明显降低,与空白对照组相比有显著性差异(t=12.58,P=0.000;t=17.97,P=0.000);塞来昔布可明显抑制HepG2细胞NF-κBp65蛋白表达水平,与空白对照组相比,差异均有统计学意义(t=4.24,P=0.013;t=6.38,P=0.003).结论:塞来昔布能有效抑制HepG2细胞NF-κB活性及NF-κBp65蛋白表达.

AIM：To investigate effects of COX-2 inhibitor celecoxib on activation of nuclear factor-kappa B （NF-κB） and on protein expression of NF-κB P65 in human liver cancer cell line HepG2. METHODS：HepG2 cells were treated with various concentrations of celecoxib. The NF-κB DNA binding activation was detected using electrophoresis mobility shift assay and proteinexpression of NF-κB p65 was determined using western blotting in HepG2 cells. RESULTS：After HepG2 cells were treated with different concentrations of celecoxib （25 and 50 μmol/L, respectively）, NF-κB DNA binding activation were signif icantly reduced （t = 12.58, P = 0.000; t = 17.97, P = 0.000） and protein expression of NF-κB p65 were signif icantly inhibited in celecoxib-treated HepG2 cells as compared with those in the empty control group （t = 4.24, P = 0.013; P = 6.38, P = 0.003）. CONCLUSION：Activation of NF-κB and expression of NF-κB p65 protein in HepG2 cells are effectively inhibited by celecoxib.